Precision Biosciences, Inc.
Associate Scientist
Yumanity Therapeutics Feb 2016 - Apr 2018
Senior Research Associate
Manus Biosynthesis Nov 2013 - Feb 2016
Research Associate
Immunetics Sep 2013 - Nov 2013
Research and Development Intern
Northeastern University May 2012 - Aug 2013
Dr Ralph Loring Lab
Education:
Northeastern University May 2013
Master of Science, Masters
Northeastern University 2011 - 2013
Masters, Pharmacology
Mumbai University 2006 - 2010
Bachelors, Bachelor of Pharmacy
Skills:
Elisa Western Blotting Pcr Gel Electrophoresis Sds Page Cell Culture Mammalian Cell Culture Hplc Bca Protein Assay Biotechnology Protein Expression Primer Design Agarose Gel Electrophoresis Rna Isolation Microscopy Cell Powerpoint Cytotoxicity Immunoprecipitation Aseptic Technique Flow Cytometry Transfection Microsoft Excel Microsoft Word Dna Quantification Binding Assays Met Luc Assay Cdna Synthesis Dna and Rna Extraction and Purification Chromatin Extraction and Crosslinking Gc Ms Fermentation Process Development Cdna High Throughput Screening
Dr. Ralph Loring's Research Lab, Northeastern University
Dec 2012 to 2000 SupervisorDr. Ralph Loring's Research Lab, Northeastern University
May 2012 to 2000 Research AssistantResidential Security Office, Northeastern University Boston, MA Dec 2011 to Dec 2012 supervisorMET Scholarship for Academic Excellence
2009 to 2010Maxwell Life Sciences Pvt. Ltd
May 2009 to Aug 2009 Trainee in the Quality Control and Quality Assurance Departments
Education:
Mumbai University Mumbai, Maharashtra Sep 2006 to Jun 2010 Bachelor of Pharmacy in Laboratory TechniquesNortheastern University Boston, MA Masters in Pharmaceutical Sciences
- Durham NC, US Jon E. Chatterton - Needham MA, US Michelle Brenda Pires - Apex NC, US
Assignee:
Precision Biosciences, Inc. - Durham NC
International Classification:
C12N 5/0783 C12N 15/11
Abstract:
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
Genetically-Modified Immune Cells Comprising A Microrna-Adapted Shrna (Shrnamir)
- Durham NC, US Jon E. Chatterton - Needham MA, US Michelle Brenda Pires - Apex NC, US
Assignee:
Precision Biosciences, Inc. - Durham NC
International Classification:
C12N 5/0783
Abstract:
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
Michelle Pires 2001 graduate of Manchester High School in Manchester, CT is on Memory Lane. Get caught up with Michelle and other high school alumni from